๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for squamous cell lung carcinoma

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC NCT06754644Phase 31 site๐Ÿ“ Jinan Qilu Pharmaceutical Co., Ltd. ยท Tests: QL2107, Pemetrexed, Carboplatin, Keytrudaยฎ A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762Phase 162 sites๐Ÿ“ Birmingham๐Ÿ“ Birmingham๐Ÿ“ Birmingham Seagen, a wholly owned subsidiary of Pfizer ยท Tests: PF-08046054, pembrolizumab GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites๐Ÿ“ New York๐Ÿ“ New York๐Ÿ“ Huntersville GI Innovation, Inc. ยท Tests: GI-101, Pembrolizumab (KEYTRUDAยฎ), Lenvatinib, GI-101A A Study of DM005 in Patients With Advanced Solid Tumors NCT06515990Phase 1, Phase 26 sites๐Ÿ“ Detroit๐Ÿ“ Dallas๐Ÿ“ Fairfax Doma Biopharmaceutical๏ผˆSuzhou๏ผ‰Co., Ltd. ยท Tests: DM005 A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies NCT05473156Phase 1, Phase 21 site๐Ÿ“ Taipei AP Biosciences Inc. ยท Tests: AP203, AP203 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site๐Ÿ“ Portland OHSU Knight Cancer Institute ยท Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites๐Ÿ“ Tucson๐Ÿ“ New Haven๐Ÿ“ Baltimore Calico Life Sciences LLC ยท Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deatโ€ฆ A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites๐Ÿ“ New York๐Ÿ“ Huntersville๐Ÿ“ San Antonio Arvinas Inc. ยท Tests: ARV-6723, Pembrolizumab, SOC Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations NCT06772623Phase 1, Phase 2126 sites๐Ÿ“ Phoenix๐Ÿ“ Fullerton๐Ÿ“ Oxnard AbbVie ยท Tests: Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Pembrolizumab, Carboplatin A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413Phase 123 sites๐Ÿ“ Goodyear๐Ÿ“ Phoenix๐Ÿ“ Duarte IDEAYA Biosciences ยท Tests: IDE892, IDE397 JMT106 Injection in the Treatment of Advanced Solid Tumors NCT07275073Phase 11 site๐Ÿ“ Zhejiang Shanghai JMT-Bio Inc. ยท Tests: JMT106 Injection A Study of IDP-001 in Advanced or Metastatic Solid Tumors NCT07602842Phase 1, Phase 26 sites๐Ÿ“ Los Angeles๐Ÿ“ Sarasota๐Ÿ“ Indianapolis InduPro, Inc. ยท Tests: IDP-001 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962EARLY Phase 15 sites๐Ÿ“ Kingswood๐Ÿ“ Wollongong๐Ÿ“ Southport Radiopharm Theranostics, Ltd ยท Tests: 177Lu-RAD204 Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC๏ผˆneoSCORE โ…ก๏ผ‰ NCT05429463Phase 31 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Sintilimab, Carboplatin, Albumin-Bound Paclitaxel A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites๐Ÿ“ Clovis๐Ÿ“ Los Angeles๐Ÿ“ Newport Beach Bristol-Myers Squibb ยท Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations NCT07336732Phase 21 site๐Ÿ“ Guangzhou Avistone Biotechnology Co., Ltd. ยท Tests: PLB1004 Effects of Infusion Timing on Treatment Response in Solid Tumors NCT07630168Phase 21 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-โ€ฆ NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations NCT06494540n/a30 sites๐Ÿ“ Bad Homburg๐Ÿ“ Berlin๐Ÿ“ Bremen AstraZeneca A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation NCT06778863Phase 121 sites๐Ÿ“ Scottsdale๐Ÿ“ Tucson๐Ÿ“ Los Angeles Clasp Therapeutics, Inc. ยท Tests: CLSP-1025 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187Phase 2, Phase 3117 sites๐Ÿ“ Springdale๐Ÿ“ Duarte๐Ÿ“ Irvine AbbVie ยท Tests: Telisotuzumab Adizutecan, Standard of Care, Osimertinib RAPA-201 Therapy of Solid Tumors NCT05144698Phase 1, Phase 21 site๐Ÿ“ Hackensack Rapa Therapeutics LLC ยท Tests: RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody) Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors NCT06171750Phase 15 sites๐Ÿ“ Bethesda๐Ÿ“ Boston๐Ÿ“ Portland Ankyra Therapeutics, Inc ยท Tests: tolododekin alfa, Cemiplimab Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion โ€ฆ ยท Tests: GTAEXS617, SoC A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC NCT07264816Phase 21 site๐Ÿ“ Wuhan Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M07D1, Pembrolizumab PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 โ‰ฅ50% Non-Squamous NSCLC NCT07416058Phase 22 sites๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Guangdong Association of Clinical Trials ยท Tests: QL1706 (bispecific antibody targeting PD-1 and CLTA-4) A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types NCT07503808Phase 115 sites๐Ÿ“ Denver๐Ÿ“ Sarasota๐Ÿ“ Detroit IDEAYA Biosciences ยท Tests: IDE034 JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation NCT06416410Phase 337 sites๐Ÿ“ Hefei๐Ÿ“ Beijing๐Ÿ“ Beijing Allist Pharmaceuticals, Inc. ยท Tests: JAB-21822, Tislelizumab, JAB-3312, Pemetrexed, Carboplatin A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) NCT06692738Phase 3328 sites๐Ÿ“ Tucson๐Ÿ“ Springdale๐Ÿ“ Anaheim AstraZeneca ยท Tests: Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel PET-imaging of Two Vartumabs in Patients With Solid Tumors NCT06645808EARLY Phase 11 site๐Ÿ“ Groningen Var2 Pharmaceuticals ยท Tests: 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07229313Phase 17 sites๐Ÿ“ Santa Monica๐Ÿ“ New Have๐Ÿ“ Camperdown Kivu Bioscience Inc. ยท Tests: KIVU-107
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy